TORONTO, Jan. 8, 2019 /PRNewswire/ - The Green Organic
Dutchman Holdings Ltd. (the "Company" or "TGOD") (TSX:TGOD)
(US:TGODF) is pleased to announce it has appointed Dr.
Caroline MacCallum and Jacques Dessureault to its Board of
Directors.
Dr. Caroline MacCallum is one of
the world's most prominent experts in cannabinoid-based medicine.
She is an internist, complex pain and cannabinoid clinician,
researcher and clinical instructor in the Department of Medicine,
an adjunct professor in the Faculty of Pharmaceutical Sciences
Program and an associate member of the Department of Palliative
Care at the University of British
Columbia. She is also the medical director at Greenleaf
Medical Clinic, where she has assessed and developed cannabinoid
treatment plans for more than 3,000 patients across Canada.
Her recent publication, Practical Consideration for Medical
Cannabis Administration and Dosing, is the first of its kind on
medical cannabis dosing. Dr. MacCallum has presented
internationally on cannabis initiatives and is the expert for
several medical cannabis courses. She is working with university
research groups, hospitals, health benefit programs, and provincial
and national committees to create cannabis guidelines for clinical
trials, safe prescribing practices and patient registries. Dr.
MacCallum has studied and remains focused on cannabis as a
substitute for opioid use and polypharmacy reduction.
"Dr. MacCallum's vast experience in cannabinoid research will be
invaluable to TGOD," commented Brian
Athaide, CEO & Director of TGOD. "She has been
recognized by her peers in the medical industry as an expert in
medical cannabis with a focus on dosing, which will be critical as
we prepare to launch a suite of multi-dose products under the
recently announced Responsible Regulation of Edible Cannabis
Products in Canada," continued
Athaide.
Mr. Jacques Dessureault has had
an extensive pharmaceutical career including significant experience
in life sciences, over-the-counter, natural health, and technology
industries. He held an international role with Novartis, as a
Global Marketing Division Head based in Basel, Switzerland, and domestic senior
executive roles as President and General Manager of Valeant
Pharmaceutical Inc., Vice-President at Bristol Myer-Squibb and
Business Unit Head and General Manager at Novartis Canada. During
Mr. Dessureault's time at Valeant Pharmaceuticals, he led all
Canadian commercial units including research and development and
international manufacturing and technical operations. Additionally,
he held responsibilities for government relations and business
acquisitions, integrations & divestments.
His entrepreneurial endeavours extend beyond the pharmaceutical
industry; Jacques is a strategic advisor with the Casting and
Performance Group of Cirque du Soleil, a board member of Optina
Diagnostics, part of the Management Committee of The Rosalind &
Morris Goodman Family Pediatric Formulations Centre of the CHU
Sainte-Justine and is involved in Academia with l'Ecole des
Sciences de la Gestion of Université du Quebec a Montreal.
"Mr. Dessureault's senior executive and entrepreneurial
experience in growing businesses, improving efficiency, and leading
research & development teams will be invaluable to TGOD,"
commented Brian Athaide, Director
and CEO of TGOD. "As we advance the research and development arms
of our Company, including our beverage science and research
division, Jacques' experience will be critical to launching new
novel and innovative product lines."
"We are incredibly fortunate to add Dr. MacCallum and
Jacques Dessureault to our Board of
Directors at such a pivotal time, as we approach production ramp-up
and our first commercial sales," commented Jeff Scott, Chairman of the Board. "The TGOD
Board now consists of independent directors with the exception of
our CEO. Both new additions possess valuable skills and extensive
experience that will greatly benefit TGOD moving forward."
Additionally, Mr. Ian Wilms has
stepped down from the Board of Directors to accommodate Dr.
MacCallum and Mr. Dessureault, effective immediately. Mr. Wilms
played an instrumental role on TGOD's Board of Directors since the
Company's formation. The Company wishes to thank Mr. Wilms for his
tireless contributions to the team and is pleased he will continue
in his corporate role of Government Affairs and Compliance.
On Behalf of the Board of Directors,
The Green Organic Dutchman Holdings Ltd.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) is a
publicly traded, premium global organic cannabis company, with
operations focused on medical cannabis markets
in Canada, Europe, the Caribbean and Latin
America, as well as the Canadian adult-use market. The Company
grows high quality, organic cannabis with sustainable, all-natural
principles. TGOD's products are laboratory tested to ensure
patients have access to a standardized, safe and consistent
product. TGOD has a funded capacity of 170,000 kgs and is building
1,382,000 sq. ft. of cultivation facilities across Ontario, Quebec and Jamaica.
TGOD's Common Shares and warrants issued under the indenture
dated November 1, 2017 trade on the
TSX under the symbol "TGOD" and "TGOD.WT", respectively.
For more information on The Green Organic Dutchman Holdings
Ltd., please visit www.tgod.ca.
www.tgod.ca
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward looking
statements in this release includes, but is not limited to,
statements about the future legalization of cannabis-infused
products in Canada, statements
about future research, development and innovation by the Company,
statements about future facility construction, statements about the
offering of any particular products by the Company in any
jurisdiction and statements regarding the future performance of the
Company. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that
term is defined in the policies of Toronto Stock Exchange) accept
responsibility for the adequacy or accuracy of this
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-green-organic-dutchman-adds-deep-medical-and-pharmaceutical-experience-to-its-board-of-directors-with-appointment-of-two-new-directors-300774446.html
SOURCE The Green Organic Dutchman Holdings Ltd.